177 related articles for article (PubMed ID: 20519806)
1. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Aoki K; Masuda K; Miyazaki T; Togashi Y; Terauchi Y
Endocr J; 2010; 57(8):667-72. PubMed ID: 20519806
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
3. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
4. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
[TBL] [Abstract][Full Text] [Related]
5. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.
Aoki K; Miyazaki T; Nagakura J; Orime K; Togashi Y; Terauchi Y
Endocr J; 2010; 57(8):673-7. PubMed ID: 20519807
[TBL] [Abstract][Full Text] [Related]
6. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
Mikada A; Narita T; Yokoyama H; Yamashita R; Horikawa Y; Tsukiyama K; Yamada Y
Diabetes Res Clin Pract; 2014 Dec; 106(3):538-47. PubMed ID: 25451890
[TBL] [Abstract][Full Text] [Related]
7. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
8. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
Vardarli I; Arndt E; Deacon CF; Holst JJ; Nauck MA
Diabetes; 2014 Feb; 63(2):663-74. PubMed ID: 24186866
[TBL] [Abstract][Full Text] [Related]
9. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels.
Aoki K; Kamiyama H; Masuda K; Kamiko K; Noguchi Y; Tajima K; Terauchi Y
Endocr J; 2014; 61(3):249-56. PubMed ID: 24389993
[TBL] [Abstract][Full Text] [Related]
10. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
Nagai E; Katsuno T; Miyagawa J; Konishi K; Miuchi M; Ochi F; Kusunoki Y; Tokuda M; Murai K; Hamaguchi T; Namba M
Endocr J; 2011; 58(10):869-77. PubMed ID: 21869539
[TBL] [Abstract][Full Text] [Related]
11. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
12. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Wu T; Ma J; Bound MJ; Checklin H; Deacon CF; Jones KL; Horowitz M; Rayner CK
Diabetes; 2014 Aug; 63(8):2776-87. PubMed ID: 24647737
[TBL] [Abstract][Full Text] [Related]
13. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
[TBL] [Abstract][Full Text] [Related]
14. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
Shibata E; Aoki K; Tajima K; Taguri M; Terauchi Y
Expert Opin Pharmacother; 2016; 17(7):889-94. PubMed ID: 26918556
[TBL] [Abstract][Full Text] [Related]
16. Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.
Ueno H; Tsuchimochi W; Wang HW; Yamashita E; Tsubouchi C; Nagamine K; Sakoda H; Nakazato M
Diabetes Ther; 2015 Jun; 6(2):187-96. PubMed ID: 26055217
[TBL] [Abstract][Full Text] [Related]
17. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
[TBL] [Abstract][Full Text] [Related]
18. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
19. Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.
Okada K; Yagyu H; Kotani K; Yamazaki H; Ozaki K; Takahashi M; Nagashima S; Osuga J; Ishibashi S
Endocr J; 2013; 60(7):913-22. PubMed ID: 23574730
[TBL] [Abstract][Full Text] [Related]
20. Effects of sitagliptin on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats.
Nishii N; Takashima S; Iguchi A; Murahata Y; Matsuu A; Hikasa Y; Kitagawa H
Domest Anim Endocrinol; 2014 Oct; 49():14-9. PubMed ID: 25010023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
